When Blood Pressure Medication Stops Working: What Changes

TL;DR30-second take

When a blood pressure medication is not controlling the number, the usual next step is a different drug rather than a higher dose. Losartan clears fast, with a 2-hour parent half-life and an active metabolite lasting 6 to 9 hours, so coverage thins out before the next dose. Telmisartan has the longest half-life of the angiotensin receptor blockers at roughly 24 hours and holds a flatter 24-hour effect. Any change is made with the prescribing physician and judged on 2 weeks of home readings.

TL;DR: If your blood pressure is still high on the pill you take, the answer is often a different pill rather than more of the same one. Some medicines wear off before the day is over. Losartan is one of those. It leaves your body fast, so your pressure can look fine in the morning and be high at night. Telmisartan is the longest-lasting medicine in that same family, and it covers a full 24 hours from one dose, so it is a common next step. A water pill like chlorthalidone often gets added on top, because most people need more than one medicine to reach a safe number. Give any change about 2 weeks of home readings before you decide it failed, since a new blood pressure pill does not show its full effect on day 1. If your number stays high on 3 medicines, ask your doctor to look for a cause, starting with a blood test for a hormone called aldosterone. Every one of these changes is made with your doctor, never on your own.

Why does a blood pressure medicine seem to stop working?

A medication that looked fine at your last visit and no longer holds the number at home has rarely lost its potency. More often it was covering part of the day and not the rest, and a week of home readings is where that first becomes visible.

Losartan is the clearest example among the angiotensin receptor blockers, the class that blocks the angiotensin II signal telling blood vessels to tighten. Losartan itself has a terminal half-life of about 2 hours. Its active metabolite, EXP3174, carries most of the effect and lasts 6 to 9 hours. Those 2 numbers describe a drug that arrives, works, and thins out before the next dose is due, which is why the ratio of losartan's trough effect to its peak effect runs roughly 50% to 95% for the top number and 60% to 90% for the bottom one. Somebody whose pressure is at goal at 10 in the morning can be well above it by 10 at night on the same tablet.

The dose ceiling makes that harder to work around. Losartan is capped at 100 mg per day, so once a person is there, the remaining lever is timing. Splitting the same daily amount into 50 mg twice a day does improve the trough, though comparisons put the gain at roughly 0.5 to 1 mmHg, which is a small return for a second daily tablet.

There is a second reason a medication underperforms that has little to do with the drug. People respond differently to different classes, and the difference is measurable. In the PHYSIC trial, 280 adults with grade 1 hypertension each took candesartan, lisinopril, amlodipine, and hydrochlorothiazide in a randomized, double-blind, repeated crossover design, and individual responses varied enough that matching the person to the drug was estimated to gain an average of 4.4 mmHg of systolic pressure over a fixed choice. Being on a medication that suits somebody else is common, and it is fixable.

Why switch from losartan to telmisartan instead of adding another pill?

Because the problem to solve is coverage across a whole day, and telmisartan is the angiotensin receptor blocker built for that job.

Telmisartan has a terminal elimination half-life of roughly 24 hours, the longest in its class. For comparison, valsartan runs around 7 hours, candesartan 9 to 13, olmesartan 12 to 14, and irbesartan 12 to 20. That long tail produces a trough-to-peak ratio approaching 100%, meaning the effect just before the next dose is close to the effect at its strongest, which is the opposite of the pattern losartan produces.

The head-to-head data follow the pharmacology. A meta-analysis of 9 randomized trials covering 2,409 patients found telmisartan lowered 24-hour ambulatory blood pressure by 2.09/1.57 mmHg more than losartan, with wider gaps during the last 6 hours of the dosing interval (2.96/2.15 mmHg) and overnight (2.70/2.08 mmHg). Those averages are modest, and they arrive in the part of the day where losartan is weakest and where almost nobody is measuring.

Changing drugs inside a class is a deliberate move rather than an admission that the first choice failed. Classes are named for a shared mechanism, and the members differ in how long they last, how they are cleared, and what else they touch. Telmisartan also carries its own outcome evidence: in ONTARGET, 25,620 patients at high cardiovascular risk were randomized to telmisartan, ramipril, or both, and telmisartan proved non-inferior to ramipril for cardiovascular death, heart attack, stroke, and heart failure hospitalization, with less angioedema. Taking both together added no benefit and more harm, which is why an angiotensin receptor blocker and an ACE inhibitor are not combined.

What do you give up, and what do you get, in that switch?

Losartan has a property no other drug in its class reliably shares, and that property deserves a look before you leave it behind.

Losartan is uricosuric, meaning it helps the kidney send uric acid out in the urine instead of pulling it back into the blood. The mechanism is inhibition of URAT1, the transporter in the proximal tubule that reabsorbs filtered uric acid. This is a losartan effect rather than a class effect, and losartan has the most consistent evidence behind it. For somebody with gout, a history of uric acid kidney stones, or a uric acid level being followed as part of a metabolic picture, starting with losartan was a considered decision, and giving it up has a cost. Our guide to high uric acid and metabolic health covers why that number gets watched at all.

Telmisartan brings a different property. It is a partial, selective agonist at PPAR-gamma, the nuclear receptor that the glitazone diabetes drugs activate fully, and it does that while it blocks the angiotensin receptor. In a 3-month trial of 40 adults with metabolic syndrome, telmisartan 80 mg lowered fasting insulin, the HOMA index, and HbA1c, while losartan 50 mg did not.

The honest reading of that finding is narrower than the enthusiasm around it. Those are surrogate markers in a small trial, and when the question was put to a hard endpoint in a large one, the advantage did not appear: in ONTARGET, new diabetes was diagnosed in 7.5% of the telmisartan arm and 6.7% of the ramipril arm. Whether telmisartan even reaches PPAR-gamma-activating concentrations in people at ordinary doses is still argued in the literature. So the metabolic angle is a fair tiebreaker between 2 otherwise similar choices, and the 24-hour coverage is the reason to make the change.

Why is another calcium channel blocker rarely the answer after ankle swelling?

Because the swelling is a class effect of the dihydropyridine calcium channel blockers, and trouble with one of them predicts trouble with the next.

Nifedipine and amlodipine belong to the same subgroup, and they widen the small arteries feeding the capillary bed far more than they widen the veins draining it. Pressure builds inside the capillary as a result, and fluid moves out into the tissue of the lower legs. That is a mechanical consequence of how the drug works rather than an allergy, and it tracks with dose. Amlodipine produces peripheral edema in about 1.8% of people at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg, and across the class, doses above half the usual maximum carry roughly 2.8 times the edema of lower doses (16.1% versus 5.7%).

The subgroup is not uniform. A network meta-analysis of the dihydropyridines ranked nifedipine highest for edema and lacidipine lowest, so a different member at a lower dose is sometimes tolerated where the first one was not. Pairing a calcium channel blocker with an angiotensin receptor blocker, an ACE inhibitor, or a diuretic also lowers the edema rate compared with the calcium channel blocker alone, because those drugs relieve the pressure on the venous side. Even so, when somebody has already had swelling bad enough to stop one dihydropyridine, going straight back to the same subgroup is the least promising direction available, and 2 other classes are still untried.

Where does a thiazide-like diuretic such as chlorthalidone fit?

As the second or third agent, and usually as the one that carries the number the rest of the way down.

Most adults with hypertension need more than one medication to reach goal, which is why guidelines have moved toward starting 2 drugs together, often in a single pill. A diuretic is the standard partner for an angiotensin receptor blocker because the 2 work on different parts of the same problem, one on vascular tone and one on sodium and fluid volume.

Chlorthalidone and hydrochlorothiazide are both thiazide-like diuretics, and on paper they are far from interchangeable. Chlorthalidone has a half-life of 40 to 60 hours against hydrochlorothiazide's 6 to 15, is 1.5 to 2 times more potent milligram for milligram, and keeps working for 48 to 72 hours after a dose. Its diuretic action begins a mean of 2.6 hours after it is taken.

That last number is where a common misunderstanding starts. The water comes off within hours, and the blood pressure effect does not follow the same schedule. A drug with a 40 to 60 hour half-life needs 8 to 12 days to reach a steady level in the blood, and the full pressure-lowering effect of a thiazide builds over weeks beyond that. Chlorthalidone is a strong long-term agent rather than a quick bridge, and expecting it to close a gap in 48 hours sets up the wrong verdict about whether it worked.

The outcome evidence is also more even than the pharmacology suggests. The Diuretic Comparison Project randomized 13,523 patients across 72 medical centers to chlorthalidone or hydrochlorothiazide and found no difference in stroke, heart attack, heart failure hospitalization, urgent revascularization, or non-cancer death over a median of 2.4 years. Chlorthalidone is a reasonable default, and hydrochlorothiazide remains a good drug.

The trade-offs matter here more than the choice between the 2. Thiazides lower potassium, which is the most frequent problem, and they can lower sodium. They also reduce uric acid excretion and can bring on gout, which deserves attention in this sequence: if losartan was chosen partly for its effect on uric acid, replacing it with telmisartan and adding a thiazide moves uric acid the wrong way twice over. A basic metabolic panel and a uric acid level a couple of weeks after the change is how that gets caught before it becomes a swollen toe at 2 in the morning.

How long does it take to know whether a change worked?

Longer than a day, and the arithmetic is knowable in advance.

Any drug taken on a repeating schedule reaches a steady level in the blood after about 4 to 5 half-lives. For telmisartan, at 24 hours, that is 4 to 5 days. For chlorthalidone, at 40 to 60 hours, it is 8 to 12 days. Before that point the drug is still accumulating, and a reading taken on day 1 is measuring a medication that has not finished arriving.

The full blood pressure effect takes longer still, because vascular tone and sodium balance adjust more slowly than plasma levels do. Telmisartan's labeling describes most of the antihypertensive effect as apparent within 2 weeks, with the maximal reduction generally reached after 4 weeks. Losartan's labeling puts a substantial effect within 1 week and the maximum at 3 to 6 weeks. So the honest window for judging a change is 2 to 4 weeks of home readings, and those readings have to be taken correctly to carry any weight, which our guide to measuring blood pressure at home walks through step by step.

The 2025 American Heart Association and American College of Cardiology hypertension guideline puts home monitoring at the center of this, recommending it both for confirming the diagnosis and for ongoing management and medication titration. Paired morning and evening readings across 2 weeks is what a good decision gets built on.

Evidence-Based Treatment

Dr. Ash reviews the research - and applies it to your specific biology.

Book a Consultation

When does the question stop being which pill and start being why?

When the number stays above goal on 3 medications at full doses. That situation has a formal name and a defined workup.

Resistant hypertension means blood pressure above goal despite 3 antihypertensive classes at maximum or maximally tolerated doses, and the 3 usually include a long-acting calcium channel blocker, a blocker of the renin-angiotensin system such as an angiotensin receptor blocker or an ACE inhibitor, and a diuretic. Before the label gets applied, 2 things have to be settled: that the medications are being taken as prescribed, and that the office readings are not a white-coat effect concealing normal out-of-office pressure.

The first test in a modern workup is for primary aldosteronism, a condition in which the adrenal glands make too much aldosterone and the kidneys hold onto sodium as a result. The 2025 guideline recommends screening every adult with resistant hypertension for it whether or not potassium is low, since most cases have normal potassium, and it says screening may be considered in everyone with stage 2 hypertension. The screen is a plasma aldosterone level, a renin level, and the ratio between them, and most blood pressure medications can be continued during it, with mineralocorticoid receptor antagonists such as spironolactone the exception. Primary aldosteronism is the most common identified cause of secondary hypertension, and it responds to targeted treatment in a way ordinary hypertension does not, which is why it has a full guide of its own here.

Imaging the kidneys and their arteries has narrower triggers than most people expect. Renal artery stenosis gets looked for when hypertension is severe with organ damage, when kidney function worsens after starting an angiotensin receptor blocker or ACE inhibitor, or when one kidney is small or the 2 differ in length by more than 1.5 cm. Duplex ultrasound and CT angiography are the usual studies. A documented home blood pressure record is often what makes that imaging approvable in the first place, which is one more argument for keeping the log.

Obstructive sleep apnea belongs on the same list and turns up more often than either of those. It is the reversible cause most frequently missed, so loud snoring, waking unrefreshed, or a partner who has noticed pauses in breathing earns a home sleep test rather than another dose increase.

Does treating an underactive thyroid raise blood pressure?

Usually the opposite, and the version of this story that circulates has the direction backwards.

Untreated hypothyroidism raises blood pressure rather than hiding it. Low thyroid hormone increases systemic vascular resistance and arterial stiffness, meaning the small arteries hold more tone while the large ones give less, and the pattern that produces is a raised diastolic number. Elevated diastolic pressure is present in roughly 30% of people with overt hypothyroidism, and the picture has been described in the hypertension literature as hypothyroid hypertension since the 1980s.

Treating the thyroid usually lowers the pressure. A meta-analysis of 29 studies found that levothyroxine reduced systolic pressure by 2.48 mmHg across 10 randomized trials in subclinical hypothyroidism, and by 4.80 mmHg systolic and 2.74 mmHg diastolic across 19 prospective follow-up studies. In the older work on overt hypothyroidism, restoring normal thyroid levels brought diastolic pressure below 90 mmHg in 9 of 16 patients who had been hypertensive while hypothyroid.

The idea that starting levothyroxine unmasks hidden hypertension has 2 more likely explanations. The first is overtreatment. Too much thyroid hormone raises heart rate and cardiac output and makes the heart more responsive to adrenaline, and that combination can push pressure up, particularly the top number. When blood pressure climbs after a thyroid dose increase, the move is to check TSH and free T4 rather than to blame the replacement itself.

The second explanation is timing. People often begin thyroid replacement during a stretch when they are being watched more closely than usual, and closer watching finds things that were already there. A number nobody had measured before is not a number that appeared.

Either way the practical answer is the same. Thyroid function belongs in a hypertension workup because it changes the picture, and a thyroid dose that has drifted high is a correctable contributor. Levothyroxine at a dose that restores normal thyroid levels is not a cause of high blood pressure.

What about the anxiety of watching the numbers?

It is part of the clinical picture rather than a distraction from it, and it does better when it gets addressed directly.

Emotion moves blood pressure by an amount you can measure. In work using a wearable cuff during ordinary working life, systolic and diastolic pressure rose 15.2 and 8.5 mmHg during stretches of strong negative emotion. A cuff inflating on the arm of somebody who is worried about what it will say is measuring the worry along with the pressure, and the reading is still accurate, it simply describes that moment rather than the baseline.

Measuring more often makes this worse rather than better. Blood pressure varies between readings for reasons that have nothing to do with disease, so checking repeatedly through the day turns up high numbers by chance that then get read as a trend. A bounded schedule, 2 readings in the morning and 2 in the evening for a defined week, carries more information than 15 checks a day and creates far less distress. Patients in qualitative research describe home monitoring as intrusive when the numbers are high or moving around, which is a good argument for setting the boundaries in advance.

Beta blockers come up in this conversation, and the honest version of the evidence is narrow. Propranolol and its relatives blunt the physical features of situational anxiety, tremor, a pounding heartbeat, visible nervousness, by blocking peripheral beta-adrenergic receptors, and the evidence supports short-term use for defined situations such as a performance or an exam. They do not treat the mental component of anxiety, and current guidance does not support them as primary treatment for generalized anxiety disorder or panic disorder. They also lower blood pressure, which is why the question comes up in a hypertension conversation at all. Whether that combination fits a given person depends on their resting heart rate, their airway history, what else they take, and what the anxiety is doing to their days, and it is a conversation with a physician rather than a plan to assemble alone. Our piece on the 2 forms of metoprolol shows how the same half-life logic plays out inside the beta blockers.

Guidance from the Clinic

"When somebody is still above goal on a medication, I want to see the whole day before I want to see a bigger dose. Losartan is a good drug that empties out fast, so a person can look controlled at breakfast and be well above goal at bedtime, and no number of extra milligrams fixes a coverage problem. Moving to telmisartan buys you the same class with a flatter 24 hours behind it. Then we give the change 2 or 3 weeks and a proper home log before anybody decides whether it worked, because a medication that has not reached steady state is being judged before it has finished arriving. And if the number still will not come down on 3 drugs, I stop asking which pill and start asking why, which usually begins with an aldosterone level."

Actionable Steps in Philly

What to bring to the conversation when your blood pressure medication is not doing the job.

Log 7 days, morning and evening. Take 2 readings each time, 2 minutes apart, on a validated upper-arm cuff with the arm resting on a table. Write down the time of day and the time you took your pill, because the gap between those 2 times is what tells your physician whether coverage is the problem.
Name the side effect that ended the last drug. Ankle swelling from a dihydropyridine, a cough from an ACE inhibitor, lightheadedness from a diuretic. Each of those narrows the next choice in a specific way, and the detail is often missing from the chart.
Ask about the half-life and the re-check date. A 4 to 5 day steady state for telmisartan and an 8 to 12 day one for chlorthalidone imply different follow-up dates, and knowing yours keeps you from judging a change too early.
Ask for the aldosterone-to-renin ratio once you are on 3 medications. The 2025 guideline recommends it in resistant hypertension whether or not potassium is low, and it is a blood draw rather than a procedure.
Answer the sleep question. Snoring, waking unrefreshed, or a partner noticing pauses in your breathing all point toward a home sleep test. Philly winters make it easy to blame that fatigue on the season for years.
Recheck a metabolic panel and uric acid 2 weeks after a change. Potassium, sodium, kidney function, and uric acid all move when these drugs change, and catching a drift early beats treating a gout flare or a low sodium later.

Key Takeaways

Losartan's parent half-life is about 2 hours and its active metabolite lasts 6 to 9 hours, so coverage thins out before the next dose and the end of the day goes untreated.
Telmisartan has the longest half-life of the angiotensin receptor blockers at roughly 24 hours, with a trough-to-peak ratio near 100% and about 2 mmHg better 24-hour control than losartan in head-to-head trials.
Losartan is uricosuric through URAT1 inhibition, which is a sound reason to have started it and a true loss when it is replaced.
Telmisartan's PPAR-gamma activity improves insulin markers in small trials and did not reduce new diabetes in ONTARGET, so it belongs in the decision as a tiebreaker.
Peripheral edema is a dose-dependent class effect of the dihydropyridine calcium channel blockers, so trouble with one predicts trouble with another.
Chlorthalidone is 1.5 to 2 times more potent than hydrochlorothiazide with a 40 to 60 hour half-life, and the Diuretic Comparison Project found their cardiovascular outcomes similar.
Steady state takes 4 to 5 half-lives and the full pressure effect takes 2 to 4 weeks, so judge a change on a 2-week home log rather than a single morning.
Untreated hypothyroidism raises blood pressure, and levothyroxine at a dose that restores normal thyroid levels usually lowers it.
Changing a blood pressure medication is done with the physician who prescribes it, never on your own.

Understanding High Blood Pressure at Home - how to take the readings any medication change gets judged on
Pressure in the Pipes: A Guide to Hypertension Management - the metabolic, autonomic, and medication levers together
Primary Aldosteronism: The Curable High Blood Pressure Doctors Miss - the first test when 3 drugs are not enough
Metoprolol: Tartrate vs Succinate - the same half-life logic inside the beta blockers
High Uric Acid: More Than Just Gout - why the uricosuric question matters when drugs change
Home Sleep Apnea Testing - the reversible cause behind a lot of stubborn hypertension

Scientific References

"Clinical pharmacokinetics of losartan." Clinical Pharmacokinetics. 2005;44(8). PubMed
"Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans." Clinical Pharmacology and Therapeutics. 1995. PubMed
Losartan potassium tablets, US prescribing information (NDA 020386). US Food and Drug Administration, 2018. FDA label
Telmisartan tablets, US prescribing information. US Food and Drug Administration, via DailyMed. DailyMed label
"A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure." Hypertension Research. 2013. PubMed
ONTARGET Investigators. "Telmisartan, ramipril, or both in patients at high risk for vascular events." New England Journal of Medicine. 2008;358(15):1547. NEJM
Benson SC, Pershadsingh HA, Ho CI, et al. "Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR-gamma-modulating activity." Hypertension. 2004;43:993-1002. PubMed
"Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome." Cardiovascular Diabetology. 2005;4:6. PubMed Central
Liang, et al. "Comparative peripheral edema for dihydropyridines calcium channel blockers treatment: a systematic review and network meta-analysis." The Journal of Clinical Hypertension. 2022. Wiley
Chlorthalidone tablets, US prescribing information (NDA 019574). US Food and Drug Administration, 2018. FDA label
"Chlorthalidone vs. hydrochlorothiazide for hypertension-cardiovascular events (Diuretic Comparison Project)." New England Journal of Medicine. 2022. PubMed
Sundström J, Lind L, Nowrouzi S, et al. "Heterogeneity in blood pressure response to 4 antihypertensive drugs: a randomized clinical trial." JAMA. 2023;329(14):1160-1169. JAMA
"2025 AHA/ACC Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults." Hypertension. 2025. AHA Journals
"Resistant hypertension: detection, evaluation, and management. A scientific statement from the American Heart Association." Hypertension. 2018. AHA Journals
He W, Li S, Zhang JA, Zhang J, Mu K, Li XM. "Effect of levothyroxine on blood pressure in patients with subclinical hypothyroidism: a systematic review and meta-analysis." Frontiers in Endocrinology. 2018;9:454. PubMed Central
"Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension." Hypertension. 1988;11(1):78. AHA Journals
"Hypertension in thyroid disorders." Frontiers in Endocrinology. 2019;10:482. Frontiers

Medical Disclaimer: This resource provides clinical context for educational purposes and describes how these decisions are reasoned through, so you can have a better conversation with your own physician. It is not a dosing guide and not a plan to follow on your own. In the world of Precision Medicine there is no "one size fits all", and the right blood pressure regimen has to be matched to your history, your kidney function, your other conditions, and your home readings. Never start, stop, or change a prescribed blood pressure medication without speaking to the physician who prescribed it.

Fishtown Medicine | Treatments

2418 E York St, Philadelphia, PA 19125(267) 360-7927 hello@fishtownmedicine.comHSA/FSA Eligible

Start your intake

Frequently Asked Questions

Common Questions

Losartan's coverage often thins out before the next dose is due, which leaves part of the day untreated even at full dose. Losartan itself has a half-life of about 2 hours, and its active metabolite EXP3174 lasts 6 to 9 hours, so the effect just before the next tablet can be substantially weaker than at its peak. The maximum is 100 mg per day, so the next move is a different drug or a second agent rather than more milligrams. Splitting 100 mg into 50 mg twice daily improves the trough by roughly 0.5 to 1 mmHg, which is usually too small to solve the problem by itself.

Telmisartan lasts longer rather than hitting harder, and the practical result is steadier 24-hour coverage. Telmisartan's terminal half-life is roughly 24 hours, the longest of the angiotensin receptor blockers, with a trough-to-peak ratio near 100%. A meta-analysis of 9 randomized trials in 2,409 patients found telmisartan lowered 24-hour ambulatory blood pressure by 2.09/1.57 mmHg more than losartan, with larger differences overnight and during the last 6 hours before the next dose.

Yes, switching between angiotensin receptor blockers is a standard and deliberate move rather than a sign the first drug failed. Drugs in one class share a mechanism and differ in half-life, elimination, and secondary properties, so one can hold blood pressure across a full day where another cannot. The switch is made by the prescribing physician, who picks the equivalent dose and sets a re-check date. Changing or stopping a blood pressure medication on your own carries a risk of rebound and is never the right path.

Ankle swelling on nifedipine is a class effect of the dihydropyridine calcium channel blockers, so amlodipine can produce it too. These drugs widen the small arteries feeding the capillaries much more than the veins draining them, which raises capillary pressure and pushes fluid into the tissue of the lower legs. The rate depends on dose: amlodipine causes edema in about 1.8% of people at 2.5 mg, 3.0% at 5 mg, and 10.8% at 10 mg. A lower dose or a different member of the subgroup is sometimes tolerated, and pairing it with an angiotensin receptor blocker or a diuretic lowers the rate.

A new blood pressure medication takes weeks to show its full effect rather than hours. Plasma levels reach steady state after 4 to 5 half-lives, which works out to 4 to 5 days for telmisartan and 8 to 12 days for chlorthalidone. The labeling for telmisartan describes most of the effect as apparent within 2 weeks and the maximum generally reached after 4 weeks, while losartan's labeling puts the maximum at 3 to 6 weeks. Fishtown Medicine judges a medication change on 2 weeks of paired morning and evening home readings rather than on the first morning after the switch.

Levothyroxine at a dose that restores normal thyroid levels usually lowers blood pressure rather than raising it. Untreated hypothyroidism increases systemic vascular resistance and arterial stiffness, and elevated diastolic pressure is present in roughly 30% of people with overt hypothyroidism. A meta-analysis of 29 studies found levothyroxine reduced systolic pressure by 2.48 mmHg across 10 randomized trials in subclinical hypothyroidism. Blood pressure that climbs after a thyroid dose increase points toward overtreatment, since excess thyroid hormone raises heart rate and cardiac output, so the step is to check TSH and free T4.

Deep-Dive Questions

Losartan inhibits URAT1, the transporter in the kidney's proximal tubule that reabsorbs filtered uric acid back into the blood, so more uric acid leaves in the urine. This uricosuric effect belongs to losartan specifically rather than to the angiotensin receptor blocker class, and losartan carries the most consistent evidence for it. A second mechanism may add to it, since blocking the renin-angiotensin system tends to increase uric acid secretion in the tubule. For a patient with gout or a rising uric acid level, that property is a sound reason to have started losartan first, and it is a true loss when the drug gets changed for better 24-hour coverage.

Telmisartan is a partial, selective PPAR-gamma agonist, and the human evidence supports better surrogate markers without yet showing better outcomes. In a 3-month trial of 40 adults with metabolic syndrome, telmisartan 80 mg lowered fasting insulin, the HOMA index, and HbA1c while losartan 50 mg did not. Tested against a hard endpoint in ONTARGET, telmisartan did not reduce new-onset diabetes compared with ramipril, at 7.5% versus 6.7%, and whether telmisartan reaches PPAR-gamma-activating concentrations at ordinary human doses remains debated. The defensible position is that the metabolic profile is a tiebreaker between similar options rather than a reason to switch on its own.

Chlorthalidone is more potent and longer-acting on paper, and the outcome evidence shows the 2 performing similarly. Chlorthalidone's half-life is 40 to 60 hours against 6 to 15 hours for hydrochlorothiazide, it is 1.5 to 2 times more potent per milligram, and its action lasts 48 to 72 hours after a dose. The Diuretic Comparison Project randomized 13,523 patients across 72 medical centers and found no difference in stroke, heart attack, heart failure hospitalization, or non-cancer death over a median of 2.4 years. Both drugs lower potassium and raise uric acid, so an electrolyte panel and a uric acid level about 2 weeks after starting either one is standard practice.

Blood pressure above goal on 3 antihypertensive classes at maximum or maximally tolerated doses, one of which is a diuretic, meets the definition of resistant hypertension and triggers a secondary workup. Adherence has to be confirmed and a white-coat effect ruled out with out-of-office readings first. The 2025 American Heart Association and American College of Cardiology guideline then recommends screening every adult with resistant hypertension for primary aldosteronism using plasma aldosterone, renin activity, and the aldosterone-to-renin ratio, whether or not potassium is low. Renal artery imaging with duplex ultrasound or CT angiography is added when kidney function worsens after an angiotensin receptor blocker or ACE inhibitor is started, when hypertension is severe with organ damage, or when one kidney is small or the 2 differ by more than 1.5 cm in length. Obstructive sleep apnea gets screened for alongside all of it.

Ready when you are